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It is a challenge to identify the molecular networks contributing to the neural basis of human speech.
Mutations in transcription factor FOXP2 cause difficulties mastering fluent speech (developmental verbal
dyspraxia, DVD), whereas mutations of sushi-repeat protein SRPX2 lead to epilepsy of the rolandic (sylvian)
speech areas, with DVD or with bilateral perisylvian polymicrogyria. Pathophysiological mechanisms driven
by SRPX2 involve modified interaction with the plasminogen activator receptor (uPAR). Independent chroma-
tin-immunoprecipitation microarray screening has identified the uPAR gene promoter as a potential target
site bound by FOXP2. Here, we directly tested for the existence of a transcriptional regulatory network
between human FOXP2 and the SRPX2/uPAR complex. In silico searches followed by gel retardation
assays identified specific efficient FOXP2-binding sites in each of the promoter regions of SRPX2 and
uPAR. In FOXP2-transfected cells, significant decreases were observed in the amounts of both SRPX2
(43.6%) and uPAR (38.6%) native transcripts. Luciferase reporter assays demonstrated that FOXP2
expression yielded a marked inhibition of SRPX2 (80.2%) and uPAR (77.5%) promoter activity. A mutant
FOXP2 that causes DVD (p.R553H) failed to bind to SRPX2 and uPAR target sites and showed impaired
down-regulation of SRPX2 and uPAR promoter activity. In a patient with polymicrogyria of the left rolandic
operculum, a novel FOXP2 mutation (p.M406T) was found in the leucine-zipper (dimerization) domain.
p.M406T partially impaired the FOXP2 regulation of SRPX2 promoter activity, whereas that of the uPAR pro-
moter remained unchanged. Together with recently described FOXP2-CNTNAP2 and SRPX2/uPAR links, the
FOXP2-SRPX2/uPAR network provides exciting insights into molecular pathways underlying speech-related
disorders.
INTRODUCTION
The development and functioning of the brain depend on very
precise and complicated molecular networks that must be
regulated both in time and in space. Animal models and
human genetic analyses have identified a large number of pro-
teins participating in crucial brain processes, but little is
known about how these individual proteins organize in regu-
latory and interacting networks. Deciphering the neurogenetic
pathways that are associated with speech-related circuits of the
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brain, while being of prime scientific importance, represents
an even more challenging problem given that speech is a
unique human trait. Nevertheless, in recent years, progress
has been made by studying families where impairment of
speech-associated processes is inherited in a monogenic
fashion. It has thus been possible to pinpoint genes that consti-
tute key entry points into the molecular networks underlying
such processes (1,2). In particular, rare loss-of-function
mutations in the FOXP2 gene (OMIM 605317) can cause a
severe speech and language disorder (OMIM 602081) (3–5).
FOXP2-related disorder is characterized by difficulties in mas-
tering sequences of oral and facial movements, impairing
speech articulation (developmental verbal dyspraxia, DVD),
accompanied by additional problems with expressive and
receptive language. FOXP2 belongs to a family of transcrip-
tion factors that have crucial functions in a wide range of
physiological processes and that are characterized by a
forkhead-box (FOX) DNA-binding domain (6). In addition
to the generation and characterization of various animal
models (7–12), subsequent studies have focussed on the
identification of FOXP2-targeted promoter regions (13,14).
At least some putative FOXP2-regulated genes are likely to
represent important players in speech-associated pathways.
Indeed, a recent study found that FOXP2 directly regulates
the CNTNAP2 gene (OMIM 604569) which encodes a
contactin-associated protein of the neurexin superfamily and
showed that polymorphisms in this target gene are associated
with specific language impairment (15).
Human genetic analyses have also implicated mutations of
the sushi-repeat protein SRPX2 (OMIM 300642) in a range
of speech-related disorders. These include epileptic (rolan-
dic/sylvian epilepsy), functional (DVD) and developmental
(bilateral perisylvian polymicrogyria) disorders of the speech
areas of the cortex (OMIM 300643, 300388) (16). Several pro-
teins that physically interact with SRPX2 have then been
identified, suggesting the involvement of the extracellular
matrix proteolysis machinery in the pathology and physiology
of speech-associated circuits. Most notably, SRPX2 was found
to directly interact with uPAR (OMIM 173391), the plasmino-
gen activator receptor of the urokinase type (also known as
PLAUR), and the SRPX2/uPAR ligand–receptor interaction
showed quantitative modification caused by a pathogenic
mutation of SRPX2 (17).
Interestingly, the uPAR promoter region was identified
among the top 100 potential FOXP2 targets in a high-
throughput chromatin-immunoprecipitation microarray
screen (ChIP-chip) using human neuronal models (14).
Given that FOXP2 and SRPX2 mutations cause related dis-
orders of speech processing and associated brain areas, this
observation raised the exciting possibility of a functional
link between the FOXP2 transcription factor on the one
hand and the SRPX2/uPAR complex on the other hand. In
the present study, we show that human FOXP2 down-regulates
both the SRPX2 and the uPAR genes and that this transcrip-
tional regulation is lost when FOXP2 bears a pathogenic
p.R553H mutation that is known to cause DVD. Moreover,
we report the discovery of a new FOXP2 coding mutation in
a patient with polymicrogyria of the left rolandic operculum
and demonstrate that it partially impairs the proper FOXP2
regulation of SRPX2 promoter activity. Our study thus
identifies a novel genetic and regulatory network that is
altered in disorders affecting speech processing and function-
ing/development of speech-related brain areas.
RESULTS
Bioinformatic detection of FOX, FOXP and FOXP2
consensus-binding sites in SRPX2 and uPAR promoters
FOX transcription factors bind to consensus DNA sites in the
cis regulatory regions of their target genes. Consensus-binding
sites with increased levels of specificity have been defined for
transcription factors of the general FOX family (FOX sites:
TRTTKRY, where R ¼ A or G, K ¼ T or G and Y ¼ T or
C), for members of the FOXP subfamily (FOXP sites:
TATTTRT) and for FOXP2 itself (FOXP2 sites: AATTTG
and ATTTGT). The FOXP2 consensus sequence ATTTGT is
contained within the FOXP sites and the FOXP sites also
conform to the more general FOX sites (18). The promoter
regions of the human SRPX2 and of the human uPAR genes
were screened in silico for the presence of FOX, FOXP and
FOXP2 sites, including approximately 1.5 kb of DNA
sequence 5′ to each corresponding and canonical transcription
start site (TSS) (SRPX2: GenBank accession no. NM_014467;
uPAR: GenBank accession no. NM_002659). In silico and
5′-RACE (rapid amplification of cDNA ends) polymerase
chain reaction (PCR) experiments confirmed that the SRPX2
and uPAR brain transcripts detected so far did not display
any alternative and more distal 5′ TSS (data not shown).
Several consensus sequences of various types (FOX, FOXP,
FOXP2) were identified in the promoter regions of both
genes (Table 1, Supplementary Material, Fig. S1). Seven
sites [SRP1–SRP7, from 3′ to 5′ of the (+) strand] were ident-
ified for SRPX2: SRP1, SRP2, SRP5 and SRP7 were of the
FOX type and SRP3, SRP4 and SRP6 fitted the consensus
for FOXP2. Six sites (UP1–UP6) were detected for uPAR:
UP1–UP3 were of the FOX type and UP4–UP6 were of the
FOXP type. Some of these sites (SRP1, UP2, UP5 and UP6)
were composed of more than one consensus sequence. The
presence of such consensus-binding sites in silico was thus
consistent with a possible regulation of SRPX2 and of uPAR
by transcription factors of the FOX family. Notably, compara-
tive searches of those consensus-binding sites (SRP1-7 and
UP1-6, respectively) in the Srpx2 and Upar promoter
sequences from chimpanzee and mouse revealed subtle to dra-
matic differences with their human promoter counterparts,
with the most obvious evolutionary modification being the
lack of any of the UP1 to UP6 consensus forkhead binding
site in the mouse Upar promoter region (Supplementary
Material, Fig. S1).
FOXP2 expression leads to a significant decrease in native
SRPX2 and uPAR transcripts
The possible regulation of SRPX2 and uPAR by FOXP2 was
then addressed by measuring by quantitative RT–PCR
(qRT–PCR) the expression of these genes in the presence of
exogenous human FOXP2 protein encoded by the major tran-
script of FOXP2 (isoform 1; GenBank accession no.
NM_014491). When HEK293T cells were transfected with a
Human Molecular Genetics, 2010, Vol. 19, No. 24 4849
 at M








construct expressing recombinant FOXP2 protein, SRPX2
mRNA levels were significantly reduced (43.6% decrease,
P, 0.05, two-tailed unpaired t-test) across replicate exper-
iments when compared with control cells transfected with
the corresponding non-recombinant vector (Fig. 1). Similarly,
the amounts of uPAR transcripts also showed significant and
replicated decrease (38.6% decrease, P , 0.01, two-tailed
unpaired t-test) in FOXP2-transfected cells (Fig. 1). This indi-
cated the existence of a functional link between FOXP2 and
both the SRPX2 and the uPAR genes.
FOXP2 represses SRPX2 and uPAR promoters
We next tested whether expression of FOXP2 could modify
the activities of the SRPX2 and of the uPAR promoters by
using a luciferase reporter assay. The promoter regions of
each gene as defined above were subcloned into the appropri-
ate vector (pGL3) 5′ to the coding sequence of the firefly
luciferase reporter gene. Either construct (pGL3-SRPX2,
pGL3-uPAR) was cotransfected with a FOXP2-containing
vector (pcDNA4/HisMax-FOXP2) or with an empty
(pcDNA4/HisMax) vector and with a b-galactosidase
expression vector (pHSV-LacZ) for the normalization of trans-
fection efficiencies. Significant and replicated repression of
the SRPX2 promoter by FOXP2 protein was detected in
pcDNA4/HisMax-FOXP2 transfected cells when compared
with pcDNA4/HisMax-transfected cells (80.2% decrease in
luciferase expression, P , 0.0005, two-tailed unpaired t-test)
(Fig. 2A). As a positive control, FOXP2 was also found to
repress the SV40 promoter (data not shown), as already
described (18). Using the same experimental procedure, dra-
matic and reproducible repression (77.5% decrease in lucifer-
ase expression, P , 0.0005, two-tailed unpaired t-test) of the
uPAR promoter by FOXP2 was shown (Fig. 2B). Together
with the qRT–PCR data, the reporter assays shown here
demonstrated the ability of the human FOXP2 protein to
repress the activities of SRPX2 and uPAR promoters.
FOXP2 directly binds to consensus sites in the SRPX2 and
uPAR promoters
Repression of the SRPX2 and uPAR promoter activities and
transcript expressions by FOXP2, and the presence of FOX,
FOXP and FOXP2 consensus-binding sites within the promo-
ter regions of SRPX2 and of uPAR, strongly suggested that
FOXP2 could directly bind to these promoter regions. We
tested this by carrying out electrophoretic mobility shift
assays (EMSAs) for the 13 consensus-binding sites (SRP1-7
and UP1-6) that had been detected in silico in the SRPX2
and uPAR promoter sequences (Supplementary Material, Fig.
S1 and Table S1). Nuclear extracts were prepared from
HEK293T cells transfected with the FOXP2 expression con-
struct (pcDNA4/HisMax-FOXP2). These extracts were able
to bind to a positive control consensus FOXP2 site as pre-
viously shown (18) and to DNA probes corresponding to the
UP2 and UP6 sites of the uPAR promoter region, as well as
to the SRP1 and SRP2 sites of the SRPX2 promoter region
(Fig. 3, Supplementary Material, Fig. S2). In contrast, no
binding was observed when using nuclear extracts prepared
from HEK293T cells transfected with an empty construct
(pcDNA4/HisMax; line pcDNA4 in each panel of Fig. 3).
The gel shifts that were observed with SRP1, SRP2, UP2
and UP6 probes were due to binding by FOXP2 protein,
since addition of an N-terminal FOXP2 antibody caused
larger complexes or ‘supershifts’ to occur (line FOXP2Ab in
each panel of Fig. 3). By comparison, no supershift was
Table 1. In silico detection of FOX, FOXP and FOXP2 consensus-binding sites
Sequencea Consensus-binding siteb Position (nt)c
FOX FOXP FOXP2
SRPX2
SRP1d TGTTTGTgagTGTTTAT + 2 2 2110; 2120
SRP2 GTAAACA + 2 2 2305
SRP3 AATTTG 2 2 + 2664
SRP4 TATTTGT + + + 2767
SRP5 TGTTGGC + 2 2 2919
SRP6 TATTTGT + + + 21260
SRP7 TGTTTGAT + 2 2 21373
uPAR
UP1 TATTTAC + 2 2 2131
UP2e ACAAACAAACAAACA + 2 2 2693; 2697; 2701
UP3 ATCAATA + 2 2 2746
UP4 ATAAATA + + 2 2832
UP5e TATTTATTTATTTAT + + 2 21160; 21164; 21168
UP6f ATAAATAAATAAATAAATA + + 2 21319; 21323; 21327; 21331
The promoter regions of the human SRPX2 and uPAR genes were screened in silico for the presence of FOX, FOXP and FOXP2 consensus-binding sites
(Supplementary Material, Fig. S1). nt, nucleotide.
aCore binding sites are represented in capital letters.
b(+) indicates the presence of a consensus-binding site and (2) indicates the absence of a consensus-binding site.
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obtained when a non-specific IgG antibody was used. Binding
to either of the SRP1, SRP2, UP2 and UP6 probes was
specific, as demonstrated by competitive impairment with
each corresponding unlabeled probe (lines UPwt2, UPwt6,
SRwt1, SRwt2 in Fig. 3). Moreover, mutant (Supplementary
Material, Table S1) and unlabeled forms of SRP1, SRP2,
UP2 and UP6 probes (lines UPmut2, UPmut6, SRmut1,
SRmut2 in Fig. 3) failed to compete with the FOXP2-binding
abilities of their labeled and wild-type counterparts, as also
shown for an irrelevant NFK unlabeled probe. Altogether,
these data demonstrated efficient specific binding of FOXP2
to consensus sites situated within the promoter regions of
both the SRPX2 and uPAR genes.
Pathogenic mutation of FOXP2 disrupts its functional
links with SRPX2 and uPAR
Rare mutations in transcription factor FOXP2 lead to DVD
(3–5); hence, targets downstream to FOXP2 are obvious can-
didates for being involved in pathophysiological mechanisms.
Based on the data presented above, SRPX2 and uPAR may be
considered particularly strong candidates because of the
demonstrated relationship between the SRPX2/uPAR
complex and disorders of the speech cortex, including DVD
itself (13,14). This question was addressed by studying the
most well-characterized aetiological mutation of FOXP2
(p.R553H), assessing its functional effects on the SRPX2 and
uPAR genes. p.R553H is a pathogenic substitution in the
DNA-binding domain of the FOXP2 protein, found in all 15
affected members of an extensively studied multigenerational
family segregating speech and language disorder (the KE
family) (3).
qRT–PCR experiments showed that, in contrast to wild-
type FOXP2, p.R553H mutant FOXP2 showed a significant
and complete loss of repression of native SRPX2 and uPAR
expression (P , 0.001 and P, 0.01, respectively, two-tailed
unpaired t-test) (Fig. 4A). Luciferase assays yielded consistent
data; the p.R553H mutation led to significant losses of repres-
sion of SRPX2 and uPAR promoters when compared with
wild-type FOXP2 (P, 0.0001 for each, two-tailed unpaired
t-test) (Fig. 4B). There even was increased activity (P ,
0.0001, two-tailed unpaired t-test) of the SRPX2 promoter in
the presence of mutant p.R553H FOXP2 (Fig. 4B), when com-
pared with cells transfected with a pcDNA4/HisMax empty
vector. Overall, these experiments demonstrated a strong
reduction in the capacity of mutant p.R553H FOXP2 protein
to down-regulate SRPX2 and uPAR.
Loss of down-regulation of SRPX2 and of uPAR by mutant
FOXP2 could be partly due to disrupted nuclear localization
(18). Indeed, alteration of FOXP2 nuclear targeting was con-
firmed in the present study by immunocytochemistry with
Xpress epitope antibody after transfection of HEK293T cells
with tagged constructs allowing expression of wild-type or
p.R553H FOXP2 (Fig. 5). While increased cytoplasmic local-
ization was clearly detected when compared with wild-type
FOXP2, a proportion of mutant p.R553H FOXP2 protein
still showed nuclear localization, consistent with previously
published data (18). FOXP2 DNA-binding capabilities can
be affected by the p.R553H substitution (18) and this question
was thus more specifically addressed with respect to the
SRPX2 (SRP1 and SRP2) and uPAR (UP2 and UP6) binding
sites using the same EMSA procedure as described above.
Mutant p.R553H FOXP2 not only displayed reduced binding
to a previously defined consensus site used as a control (18),
but also showed unambiguous impairment (of variable
degree) in its ability to bind to the consensus SRP1, SRP2,
UP2 and UP6 target sites in the promoter regions of SRPX2
and of uPAR (Fig. 3).
A novel FOXP2 missense mutation in a patient with left
opercular polymicrogyria partially impairs regulation of
SRPX2
The regulatory link between FOXP2 and SRPX2 prompted us
to screen for FOXP2 mutations in a series of 32 patients pre-
senting with disorders of the speech cortex that can be caused
by SRPX2 mutations [rolandic epilepsy (RE) with speech
impairment, perisylvian polymicrogyria] or with other dis-
orders of the same clinical spectrum [continuous
spike-and-waves during sleep (CSWS) and Landau–Kleffner
syndromes] (19). One heterozygous missense mutation
(c.T1591C) of FOXP2 was found in a girl of Turkish origin
presenting with focal epilepsy with CSWS and cognitive and
language deficits. Magnetic resonance imaging (MRI)
showed polymicrogyria of the left rolandic operculum
(Fig. 5A and B). Her father also carried the mutation
(Fig. 5B) but did not have any neurological problem and
had normal MRI (data not shown), as verified by three inde-
pendent and experienced radiologists and neuropaediatricians.
The proband’s sister and brother also had the mutation (data
not shown). Their clinical phenotype could not be fully
assessed and no MRI was performed, but no obvious neuro-
logical abnormality was noted. No compound heterozygous
mutation was found in the patient and her mother and their
karyotypes were normal; comparative genomic hybridization
analysis of the patient’s DNA using Agilent 60K oligonucleo-
tides array did not detect any abnormality in the FOXP2
genomic area (data not shown). The mutation replaced a
highly conserved methionine residue with a threonine
Figure 1. qRT–PCR experiments. Wild-type FOXP2 protein down-regulates
the native SRPX2 and uPAR genes. qRT–PCR experiments were performed
from HEK293T cells transfected with pcDNA4/HisMax-FOXP2 construct.
Expression changes are given as the mean of log2 expression ratios of cells
transfected with pcDNA4/HisMax-FOXP2 compared with cells transfected
with non-recombinant pcDNA4/HisMax vector and are normalized for equal
expression of the GAPDH internal control. Values represent the mean of com-
parisons of five independent cDNA syntheses. P-values were calculated using
two-tailed unpaired t-test. ∗P, 0.05 and ∗∗P , 0.01.
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(p.M406T) within the leucine-zipper domain of FOXP2 and
was neither found in the SNP database (http://www.ncbi.
nlm.nih.gov/snp at NCBI) nor in 222 unrelated control indi-
viduals (33 of Turkish origin + 189 Caucasians). In analyses
of HEK293T cells transfected with tagged mutant constructs,
p.M406T led to partial alteration in the nuclear localization
of FOXP2 (Fig. 5C). Luciferase reporter assays were then con-
ducted and showed that the p.M406T mutation led to signifi-
cant loss of repression of the SRPX2 promoter, when
compared with wild-type FOXP2 (P , 0.0001, two-tailed
unpaired t-test) (Fig. 5D). In contrast to p.R553H (Fig. 4B),
p.M406T FOXP2 partially retained the ability to repress
SRPX2 promoter activity and had no effect on the repression
of uPAR promoter activity (Fig. 5D).
DISCUSSION
The present study characterized a novel molecular regulatory
network associated with the disorders of cortical speech areas
and of speech processing. In particular, we demonstrated the
direct down-regulation of SRPX2, a gene implicated in
X-linked RE associated with DVD (RESDX syndrome) or
with bilateral perisylvian polymicrogyria (BPP) (16), by the
FOXP2 transcription factor, mutated in people with autoso-
mal dominant DVD (3–5). Similarly, FOXP2 also down-
regulated the uPAR gene, which encodes a receptor of
SRPX2, which in turn displays a modified interaction with
the mutant SRPX2 protein (17). Hence, our study shows
that FOXP2 co-regulates the expression of the ligand
SRPX2 and of its receptor, uPAR. That there is connectivity
between FOXP2 targets had already been suggested (14); as
far as we are aware, this is the first clear demonstration of
regulated targets with a direct interaction between them.
Our findings are also in good agreement with the usual down-
regulating effects of FOXP2 on its direct targets as identified
by ChIP-chip experiments (13,14); furthermore, whereas the
SRPX2 promoter region was not present on the microarrays
used in these previous studies, uPAR was detected among
the 100 most significant FOXP2 targets in human neuronal
models (14).
Wild-type FOXP2 was able to bind to several consensus
sites in the promoter regions of SRPX2 (SRP1 and SRP2)
and uPAR (UP2 and UP6). None of these four sites corre-
sponded to the canonical and specific FOXP2 consensus
sequences; instead, SRP1, SRP2 and UP2 were of the FOX
type and UP6 of the FOXP type. The binding of FOXP2 to
less stringent FOX or FOXP sites has already been observed
(14). Among the four FOXP2 binding sites studied here,
three (SRP1, UP2 and UP6) consisted of more than one fork-
head consensus sequence; this situation would be consistent
with the binding of FOXP2 through homo- or heterodimeriza-
tion, as already proposed (20), and may also favor cross-
binding to FOX and FOXP consensus sites. Both the
regulations of SRPX2 and of uPAR were abolished by a
p.R553H FOXP2 mutation that is known to cause DVD (3);
the expression of p.R553H FOXP2 even led to significant
increases in the activity of the SRPX2 promoter when com-
pared with the control situation. This latter result is in line
Figure 2. Luciferase reporter assays. Wild-type FOXP2 protein down-regulates the activities of the SRPX2 (A) and of the uPAR (B) promoters. Either of the
SRPX2 (pGL3-SRPX2) and uPAR (pGL3-uPAR) promoter constructs was co-transfected into HEK293T cells with FOXP2-containing (pcDNA4/HisMax-
FOXP2) or with empty (pcDNA4/HisMax) vector and with a b-galactosidase expression vector (pHSV-LacZ) for the normalization of transfection efficiencies.
In parallel, an empty (promoterless) vector (pGL3-basic) was transfected with pcDNA4/HisMax-FOXP2 and with pHSV-LacZ. Transcriptional activities were
determined by quantifying the luciferase activity of cellular extracts prepared 48 h after transfection. Data show the mean+SD relative activity from three
experiments done in triplicate. Statistical significances were determined by two-tailed unpaired t-test. ∗∗∗P , 0.0005.
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with the previous investigations of the p.R553H mutant form
using the SV40 promoter as a reporter (18) and may be due
to the interference of the mutant protein with the transactiva-
tion capabilities of endogenous FOXP proteins expressed in
HEK293T cells. Consistent with the losses of regulation of
SRPX2 and of uPAR, mutant FOXP2 also showed partial
alteration in nuclear localization and disrupted binding to the
SRPX2 and uPAR target sites. Altogether, these data argued
in favor of a pathogenic involvement of the FOXP2-SRPX2/
uPAR regulatory link.
The data presented here demonstrated the existence of a
novel regulatory and functional link, FOXP2-SRPX2/uPAR,
displaying impairment in various disorders involving
speech-related areas and networks. These findings are reminis-
cent of the recent functional link that was found between
FOXP2 and the gene coding for the contactin associated
Figure 3. Electrophoretic mobility shift assays. FOXP2 directly binds sites identified within the SRPX2 and uPAR promoters. EMSAs were used to determine
whether direct interactions occurred between FOXP2 and the promoter regions of the SRPX2 and uPAR genes. DNA probes were designed based on the presence
of predicted FOX, FOXP and FOXP2-binding sites (Table 1, Supplementary Material, Table S1). Radiolabeled probes that had shown binding in earlier exper-
iments (Supplementary Material, Fig. S2) were incubated with nuclear extracts taken from HEK293T cells transfected with either an empty vector (pcDNA4),
wild-type FOXP2 or FOXP2.R553H. The binding of FOXP2 to a known consensus binding site (CONSENSUS) is shown as a positive control. Binding assays
were also performed in the presence of competition from unlabeled wild-type (wt), mutant (mut) and irrelevant (NFK) probes. In each case, FOXP2 binding to
the labeled wild-type probe was efficiently impaired via competition with unlabeled wild-type competitor probe, but not by mutant or irrelevant competitor
probes, displaying the specificity of the interaction. Addition of an antibody directed to FOXP2 (FOXP2 Ab) caused a supershift to occur in each case, an
effect not observed when an irrelevant control antibody (IgG) was added. This confirmed that the identity of the protein causing gel retardation is indeed FOXP2.
Human Molecular Genetics, 2010, Vol. 19, No. 24 4853
 at M








protein-like 2, CNTNAP2 (15). Whereas FOXP2 mutations
cause DVD accompanied by expressive and receptive
language deficits, CNTNAP2 shows genetic association not
only with specific language impairment (15) but also with
autism (21–23) and with epilepsy and schizophrenia (24).
Moreover, a homozygous CNTNAP2 mutation in Amish chil-
dren has been shown to cause focal epilepsy followed by
language regression, behavioral problems and mental retar-
dation (25). Hence, both the FOXP2-CNTNAP2 and the
FOXP2-SRPX2/uPAR regulatory pathways make direct and
functional molecular links between various disorders of the
brain that are diagnostically distinct, but are well known to
share clinical, epidemiological and neurobiological features.
Epilepsy, autism, DVD and specific language impairment
may well rely on partially overlapping molecular networks.
More precisely, there is long known and increasing evidence
for a connection between idiopathic focal epilepsies—RE par-
ticularly—on the one hand and cognitive, attention, speech
and reading disabilities on the other hand (26–29). FOXP2
regulates the expression of both components of the SRPX2/
uPAR complex involved in epileptic seizures of the rolandic
area; interestingly, the centrotemporal electroencephalo-
graphic hallmark of RE has shown increased frequency in
patients with DVD (30). To the best of our knowledge, no
rolandic seizure has ever been reported in people with
FOXP2 mutations. When compared with mutations in
SRPX2, mutations in FOXP2 very likely disrupt the regulation
of many more pathways that may have modulatory effects on
the susceptibility to epileptic seizures.
A novel p.M406T FOXP2 heterozygous mutation was found
in a girl with developmental defects of the speech cortex, i.e.
polymicrogyria of the left rolandic operculum, hence recalling
Figure 4. Regulation of, and binding on, the SRPX2 and uPAR promoters is altered by a pathogenic p.R553H FOXP2 mutation. (A) qRT–PCR experiments
showing loss of down-regulation of the native SRPX2 and uPAR expressions by mutant FOXP2. Expression changes are given as the mean of log2 expression
ratios of HEK293T cells transfected with pcDNA4/HisMax-FOXP2 (wild-type FOXP2) or with pcDNA4/HisMax-R553H (mutant p.R553H FOXP2), when com-
pared with HEK293T cells transfected with non-recombinant pcDNA4/HisMax vector, and are normalized for equal expression of the GAPDH internal control.
Values represent the mean of comparisons of five independent cDNA syntheses. P-values were calculated using two-tailed unpaired t-test. ∗P , 0.05, ∗∗P , 0.01
and ∗∗∗P, 0.001. (B) Luciferase reporter assays showing loss of down-regulation of the SRPX2 and uPAR promoter activities by mutant p.R553H FOXP2.
Either of the SRPX2 (pGL3-SRPX2) and uPAR (pGL3-uPAR) promoter constructs was co-transfected into HEK293T cells with FOXP2-containing
(pcDNA4/HisMax-FOXP2 or pcDNA4/HisMax-R553H) or with empty (pcDNA4/HisMax) vector and with a b-galactosidase expression vector (pHSV-LacZ)
for the normalization of transfection efficiencies. In parallel, the empty (promoterless) vector (pGL3-basic) was transfected with pcDNA4/HisMax-FOXP2 and
with pHSV-LacZ. Transcriptional activity was determined by quantifying the luciferase activity of cellular extracts prepared 48 h. after transfection. Data
show the mean+SD relative activity from three experiments done in triplicate. Statistical significances were determined by two-tailed unpaired t-test.
∗∗∗∗P , 0.0001.
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Figure 5. Novel p.M406T FOXP2 mutation in a patient with polymicrogyria of the left rolandic operculum partially impairs proper regulation of SRPX2.
(A) MRI (axial inversion recovery section) of the patient with left opercular polymicrogyria. (B) c.T1591C mutation of FOXP2. The nucleotide sequences
and translations are shown above the direct sequencing trace from PCR-amplified fragment. Top: Section of a wild-type sequence in the unaffected mother
(white circle). Middle: Section of a sequence with the mutation in the carrier father (dotted square). Bottom: Section of a sequence with the mutation in the
affected proband (full-blackened circle). Two more siblings were carriers, but did not show obvious neurological problems, although no MRI was performed
(sequence traces not shown). (C) p.R553H and p.M406T mutant FOXP2 proteins display altered intracellular localizations. HEK293T cells were transfected
with pcDNA4/HisMax (mock) vector (top, left), with pcDNA4/HisMax-FOXP2 (wt) vector (bottom, left), with pcDNA4/HisMax-R553H (p.R553H) vector
(top, right) or with pcDNA4/HisMax-M406T (p.M406T) vector (bottom, right). Wild-type FOXP2 displayed unambiguous nuclear localization. Mutant
p.R553H FOXP2 showed both nuclear and cytoplasmic localizations, as already described (18), and p.M406T FOXP2 also showed altered nuclear targeting.
HisMax-tag fusion protein FOXP2 was detected using an antibody to the N-terminal XpressTM tag (green). Blue: nuclear DAPI staining. (D) Luciferase reporter
assays showing partial loss of down-regulation of the SRPX2 promoter activity by mutant p.M406T FOXP2. Activity of the uPAR promoter remained unchanged.
Either of the SRPX2 (pGL3-SRPX2) and uPAR (pGL3-uPAR) promoter constructs was co-transfected into HEK293T cells with FOXP2-containing (pcDNA4/
HisMax-FOXP2 or pcDNA4/HisMax-M406T) or with empty (pcDNA4/HisMax) vector and with a b-galactosidase expression vector (pHSV-LacZ) for the nor-
malization of transfection efficiencies. In parallel, an empty (promoterless) vector (pGL3-basic) was transfected with pcDNA4/HisMax-FOXP2 and with
pHSV-LacZ. Transcriptional activity was determined by quantifying the luciferase activity of cellular extracts prepared 48 h after transfection. Data show
the mean+SD relative activity from three experiments done in triplicate. Statistical significances were determined by two-tailed unpaired t-test. NS, not sig-
nificant (P . 0.05), ∗∗∗P, 0.001 and ∗∗∗∗P , 0.0001.
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an SRPX2-related phenotype. The proband’s father carried the
mutation but did not manifest the disease and had normal
MRI; this obviously argues against a simple causal role.
Two other sibs also carried the mutation but their phenotype
could not be ascertained and no MRI was done. This situation
is reminiscent of that observed in other genetic cases: for
instance, SHANK3 mutations can be found in patients with
autistic syndrome disorder and their unaffected relatives
(31). Nevertheless, several arguments account for a likely par-
ticipation of the p.M406T FOXP2 mutation as a susceptibility
factor to the polymicrogyria reported here. First, functional
MRI abnormalities of various regions, including Broca’s
area in the inferior frontal gyrus, have already been detected
in people carrying FOXP2 mutations (32). The aforemen-
tioned FOXP2 target, CNTNAP2, shows enriched expression
in frontal gray matter of human fetal brain tissue (33), and
FOXP2 itself displays high levels of expression in the devel-
oping perisylvian cortex (34). Secondly, p.M406T was
neither found in 222 control individuals nor in available data-
bases of human variation. Furthermore, the methionine residue
that is mutated is highly conserved across evolution, and
p.M406T occurred in a leucine zipper domain that is crucial
for the dimerization and subsequent DNA binding of FOXP2
(20). Thirdly, the present study showed that there is a direct
functional link between FOXP2 and the SRPX2/uPAR
complex that in turn has been implicated in bilateral perisyl-
vian polymicrogyria that predominated on the left side
(16,17). More importantly, p.M406T was shown here to
have functional consequences in vitro: it not only led to
altered pattern of nuclear localization of FOXP2, but also
to significantly reduced, albeit still active, regulation of the
SRPX2 promoter activity; interestingly also, the promoter
activity of uPAR remained unchanged. Hence, the effect of
p.M406T was more subtle than that of p.R553H. This is con-
sistent with the difference in the genetic influences associated
with those two mutant FOXP2 proteins. p.M406T retained
partial functionality and the effects of this risk factor are
likely to be modulated by genomic background, environmental
influences and stochastic developmental events, hence leading
to incomplete penetrance in the pedigree reported here.
Although the existence of compound heterozygous mutation
cannot be firmly excluded, no other FOXP2 mutation was
found in the patient and her mother and conventional as
well as molecular cytogenetics did not reveal any gene
rearrangement. Moreover, homozygous and compound hetero-
zygous mice lacking functional Foxp2 not only have severe
developmental delays and general motor dysfunction but
also do not survive beyond 3 weeks after birth (10).
FOXP2 shows evidence of recent positive selection (35).
FOXP2 underwent two non-synonymous changes since the
human–chimpanzee split and cell-based studies suggest that
several FOXP2 target genes may be differentially regulated
by human and chimpanzee versions of the protein (36).
SRPX2 also exhibited an accelerated rate of non-synonymous
substitutions in the human lineage; although there was insuffi-
cient statistical power to demonstrate the action of positive
selection (37), the human-specific SRPX2 evolutionary
change was associated with modified interaction with uPAR
(17). From this evolutionary viewpoint, differences in the
regulation of expression of SRPX2 and of uPAR by FOXP2
in different species might have been important. The SRP2 con-
sensus site is conserved in the mouse and chimpanzee Srpx2
promoters. In contrast, SRP1, while being slightly different
between the human and chimpanzee promoters, was not
detected in the mouse Srpx2 promoter. Interestingly, the
UP2 and UP6 FOXP2-binding sites of the human uPAR pro-
moter region were conserved between human and chimpanzee
but did not exist at all in the promoter region of murine Upar.
Although preliminary, these data may suggest that the regu-
lations by FOXP2 of uPAR and of SRPX2 have appeared or
have been modified during evolution since the rodent–
primate split.
Generally, the functioning and development of brain cir-
cuits underlying human speech result from complex sequential
processes that must be tightly regulated. The emerging picture
arising from the study of various speech-related disorders (RE,
DVD, BPP) is that of a complicated and intertwined network
of regulation and interaction comprising FOXP2, uPAR,
SRPX2 as well as CNTNAP2. Moreover, the situation is
likely to be considerably more complex: FOXP2 certainly
has many more functional targets (13,14), and uPAR (38,39)
as well as SRPX2 (40,41) expression can be modulated by
other transcription factors. In addition to uPAR, SRPX2
itself has many more possible partners (17), some of which
such as FBN1 (Fibrillin-1) or PCSK6 (Subtilisin-like propro-
tein convertase 4, PACE4) also showed significant enrichment
after ChIP-chip FOXP2 experiments (14). It is thus expected
that alterations of several other molecular pathways will be
found in future studies of speech-related syndromes. As
such, it will be crucial to identify and study each of them,
and then try to integrate how and when they may interfere
with each other and with the development/functioning of
speech-related areas and networks. From this viewpoint, the
identification of the FOXP2-SRPX2/uPAR functional and
genetic link, and its alteration by a FOXP2 pathogenic
mutation, represent important entry points for deciphering
the complicated regulatory networks of molecules that go
awry in speech-related disorders. Together with recently
described FOXP2-CNTNPA2 genetic and SRPX2/uPAR pro-
teomic links, the present findings make novel genetic and mol-
ecular links between distinct phenotypes that share clinical,
epidemiological and neurobiological features, including
autism, epilepsy of speech-related areas and developmental
speech and language disorders.
MATERIALS AND METHODS
In silico analyses and 5′-RACE experiments
The promoter regions of the human SRPX2 (GenBank accession
no. NM_014467) and uPAR (GenBank accession no.
NM_002659) genes were taken from the UCSC human
genome browser web site (March 2006 human reference
sequence, NCBI Build 36.1; http://genome.ucsc.edu/) and
were screened in silico for the presence of FOX, FOXP and
FOXP2 consensus-binding sites within 1.5 kb of DNA sequence
5′ to each canonical TSS and using the DNA Pattern
Find program of the Sequence Manipulation Suite (42) at
http://bioinfo.unice.fr/softwares/sms2/dna_pattern.html. The
possible existence of alternative transcripts with more distal
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5′ TSS was tested in silico and by RACE performed from human
whole-brain total RNA using FirstChoicew RLM-RACE Kit
(Ambion) according to the manufacturer’s instructions and
using the following primers: 5′-RACE Outer Primer and
SRPX2-Race1 (5′-tagaacgagtggctcctggtctgt) or uPAR-Race1
(5′-gacgcaggtgtggagcagca) for the first PCR and 5′-RACE
Inner Primer and SRPX2-Race2 (5′-cggcctccgggattctgttaa-
cactgc) or uPAR-Race2 (5′-tgcgcggggtccctgcacgtcttctctcctt)
for the nested PCR. Consensus-binding sites were as defined
previously (14): for the general FOX family, TRTTKRY,
where R ¼ A or G, K ¼ T or G and Y ¼ T or C; for members
of the FOXP subfamily, TATTTRT; for FOXP2, AATTTG
and ATTTGT. For evolutionary comparisons, the promoter
regions of Pan troglodytes Srpx2 (GenBank accession no.
NM_001135656) and Upar (GenBank accession no.
NM_001009031) genes and of Mus musculus Srpx2
(GenBank accession no. NM_026838) and Upar (GenBank
accession no. NM_011113) genes were taken from the corre-
sponding UCSC chimpanzee [Chimp Mar. 2006 (panTro2)
assembly, Build 2 Version 1, October 2005] and mouse
[Mouse July 2007 (mm9) assembly, Build 37] genome browsers
at http://genome.ucsc.edu/, respectively.
Constructs and site-directed mutagenesis
For luciferase gene reporter experiments, the promoter regions
of SRPX2 and of uPAR as defined above were amplified by
PCR from genomic DNA and subcloned into the pGL3
vector (Promega), 5′ to the coding sequence of the firefly luci-
ferase reporter gene. Primers used were as follows: PROM_
SRPX2.F: 5′-aaaaaggtacctaaactctgggagctggaga; PROM_
SRPX2.R: 5′-aaaaaaagctttttatggtattttgtgcccttt; PROM_UPAR.
F: 5′-aaaaactcgagctggcgtgcccctgtaa; PROM_UPAR.R: 5′-aaa
aaaagcttggtccctgcacgtcttctct. Direct sequencing was used to
confirm the integrity of each construction. The pcDNA4/
HisMax-FOXP2 vector has been used previously (18). Quick-
Change Site-Directed Mutagenesis kit (Stratagene) was used
to generate the pcDNA4/HisMax-R553H and pcDNA4/
HisMax-M406T vectors allowing the expression of the
mutant forms (p.R553H and p.M406T) of FOXP2. The follow-
ing primers were used: FOXP2.R553H-F: 5′-gcaacttggaagaatg
cagtacatcataatcttagcctgc and FOXP2.R553H-R: 5′-gcaggcta
agattatgatgtactgcattcttccaagttgc; FOXP2.M406T-F: 5′-cgtcttc
aagcaatgacgacccacttgcacatgc and FOXP2.M406T-R: 5′-gcat
gtgcaagtgggtcgtcattgcttgaagacg. The presence of the desired
mutations (c.G2032A and c.T1591C, corresponding to
p.R553H and to p.M406T, respectively, with nucleotide pos-
itions as in NM_014491) and the absence of any other
unwanted mutation were confirmed by direct sequencing.
Cell cultures and transfections
HEK293T cells were grown in 5% CO2 at 378C in Dulbecco’s
modified Eagle’s medium (Lonza) supplemented with 2 mM
L-of glutamine, 100 U/ml of penicillin, 100 mg/ml of strepto-
mycin and 10% fetal calf serum. One day before transfection,
cells were seeded in six-well plates with a concentration of 105
cells/well. When cells reached 70–80% confluence, they were
transiently transfected using the Lipofectamine PlusTM reagent
(Invitrogen) according to the manufacturer’s instructions.
Real-time RT–PCR
HEK293T cells were transfected with expression vectors for
either wild-type FOXP2 (pcDNA4/HisMax-FOXP2) or
mutant FOXP2 (pcDNA4/HisMax-R553H), or with an empty
vector (pcDNA4/HisMax). Cells were harvested 48 h after
transfection and total RNAs were extracted in TRIzol
reagent. One microgram of total RNA was reverse-transcribed
using random hexamers and the Superscript(R) II RNase H
reverse transcriptase (Invitrogen), according to the manufac-
turer’s instructions.
PCR primers were designed for the SRPX2 and uPAR genes
as well as for the GAPDH (glyceraldehyde-3-phosphate deshy-
drogenase) and B2M (beta-2-microglobulin) control genes,
using the Universal Probe Library Assay Design Center at
http://www.roche-applied-science.com/. Primers were: for
SRPX2: forward 5′-agggcacaaaataccataaaaca and reverse
5′-gaagtcagccatcaattaacttctaa; for uPAR: forward 5′-cctctgc
aggaccacgat and reverse 5′-tggtcttctctgagtgggtaca; for
GAPDH: forward 5′-tccactggcgtcttcacc and reverse 5′-ggcag
agatgatgaccctttt; for B2M: forward 5′-taggagggctggcaacttag,
and reverse 5′-cttatgcacgcttaactatcttaacaa. Quantitative PCR
was carried out using LightCyclerw 480 SYBR Green I
Master (Roche) in the LightCyclerw 480 system (Roche).
All primer pairs were optimized to ensure specific amplifica-
tion of the PCR product and the absence of any primer
dimer. Quantitative PCR standard curves were set up for all.
Quantification was calculated using the comparative CT
method. Fold changes were reported for cells transfected
with either of wild-type (pcDNA4/HisMax-FOXP2) or
mutant (pcDNA4/HisMax-R553H) FOXP2-containing
expression vector and when compared with cells transfected
with empty (pcDNA4/HisMax) vector. Relative quantification
was performed using GAPDH as reference gene; the other
control gene B2M did not show any significant variation
(data not shown). For each gene, fold changes were reported
as the mean of comparisons between five cDNA preparations.
Data were expressed as mean+SEM. Statistical significance
was assessed using unpaired t-tests (two-tailed).
Luciferase reporter assays
HEK293T cells were cotransfected in six-well plates with
(i) 150 ng of the appropriate reporter construct (pGL3-basic
for negative control, pGL3-promoter for positive control,
pGL3-SRPX2 or pGL3-uPAR construct for the analysis of
each corresponding promoter activity), (ii) 150 ng of
pHSV-LacZ for normalization and (iii) 1.2 mg of a construct
for either the expression of FOXP2 wild-type (pcDNA4/
HisMax-FOXP2), or the expression of mutant FOXP2 proteins
(pcDNA4/HisMax-R553H or pcDNA4/HisMax-M406T), or
no FOXP2 expression (empty pcDNA4/HisMax). Forty-eight
hours after transfection, cells were lysed with 150 ml of Repor-
ter Lysis Buffer (Promega). Firefly luciferase activity was
quantified using the Luciferase Assay System (Promega) on
a LB9507 Luminometer (Lumat). LacZ activity was measured
using the b-Galactosidase Enzyme Assay System (Promega)
on a NanoDropTM 1000 (Thermo Fisher Scientific). All trans-
fections were performed in triplicate and repeated in three
independent experiments (nine biological replicates in total).
Human Molecular Genetics, 2010, Vol. 19, No. 24 4857
 at M








The relative luciferase activities were then calculated with cor-
rection for transfection by b-galactosidase activity. Data were
expressed as mean+SEM. Statistical significance was
assessed using unpaired t-tests (two-tailed).
EMSA experiments
HEK293T nuclear extracts (transfected with FOXP2,
FOXP2.R553H or the pcDNA4 empty vector control) were
prepared as described previously (18). Probes were designed
as 24–30 nucleotide oligomers (Supplementary Material,
Table S1) based around the predicted binding sites in the
SRPX2 and uPAR promoters (Table 1). Mutant promoters
were the same, however, with the core predicted binding site
replaced (Supplementary Material, Table S1). A consensus
probe previously shown to be efficiently bound by FOXP2
was used as a positive control (5′-agcttaaacaagacaacacaaataa)
and an irrelevant promoter sequence (corresponding to an
NFK binding site) was used as a negative control
(5′-agctccgggggtgatttcactccccg). Oligonucleotide labeling
and DNA-binding reactions were performed as described pre-
viously (18). Where unlabeled competitor probes were used to
confirm specificity of DNA binding, they were added in
10-fold excess and pre-incubated at room temperature for
15 min, before the addition of labeled probe. Supershift
assays were performed via pre-incubation of an N-terminal
FOXP2 antibody (N-16; Santa Cruz) or a normal goat IgG
negative control antibody (Santa Cruz) with nuclear lysates
for 15 min at room temperature prior to the binding reaction.
Protein–DNA interactions were resolved on a 5% polyacryl-
amide Tris/borate/EDTA gel.
Immunocytochemistry experiments
HEK293T cells were cultured on cover slips (LabTek I,
Dutcher) and transfected with either a wild-type FOXP2-
containing vector (pcDNA4/HisMax-FOXP2) or with a
mutant FOXP2-containing vector (pcDNA4/HisMax-R553H
or pcDNA4/HisMax-M406T) or with an empty vector
(pcDNA4/HisMax). Forty-eight hours after transfection, cells
were fixed using 4% paraformaldehyde solution at room temp-
erature. HisMax-tag fusion protein FOXP2 was detected using
an antibody to the N-terminal XpressTM tag and nuclei were
counterstained with DAPI (4′,6-diamidino-2-phenylindole).
Images were captured with a fluorescence microscope
(Leica, DMR) equipped with a CoolSnap camera.
Genetic screening
Thirty-two patients presenting with various related disorders,
such as RE with DVD, perisylvian polymicrogyria, CSWS
and Landau–Kleffner syndromes, were subjected to careful
clinical, neuropsychological and electroencephalogram
recordings, as well as to neuroimaging examinations whenever
appropriate. All patients had given informed consent for the
collection of blood samples and DNA extractions. In particu-
lar, one girl with the p.M406T FOXP2 mutation had polymi-
crogyria of the left rolandic operculum as shown by MRI;
she had focal epilepsy with CSWS and cognitive and language
impairments. Pregnancy, birth and initial development were
normal. Language acquisition was delayed with no clear
regression. She had mental retardation with verbal, perform-
ance and full-scale IQs around 40 that remained unchanged
from 7 to 16 years old. CSWS were detected at 6 years old
and disappeared at the age of 10 years old. She also had
right hemiparesia. At 25 years old, the patient was under
50 mg/day of phenobarbital and had rare nocturnal focal sei-
zures; she still had cognitive and language deficits. The
patient was born from unaffected parents. As her father also
carried the mutation, he was submitted to MRI examination
which did not reveal any abnormality (data not shown). The
proband’s sister and brother also carried the mutation; they
did not show any obvious neurological disorder upon prelimi-
nary examination and no MRI was done. The whole coding
sequence of the FOXP2 gene was screened for mutations by
direct sequencing of each exon and its surrounding intronic
sequences. Both strands of each corresponding PCR product
(list of primers upon request) were sequenced with an
ABI3700 DNA Analyzer (Applied Biosystems) and the data
were analyzed with the Genalys 3.0 software (43).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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